Related Experiment Video
Updated: Jul 11, 2025

A Method for Mouse Pancreatic Islet Isolation and Intracellular cAMP Determination
Published on: June 25, 2014
Inhibition of polyamine biosynthesis preserves β cell function in type 1 diabetes
Emily K Sims1, Abhishek Kulkarni2, Audrey Hull3
1Division of Pediatric Endocrinology and Diabetology, Herman B. Wells Center for Pediatric Research, Center for Diabetes and Metabolic Diseases, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
Abstract:
In preclinical models, α-difluoromethylornithine (DFMO), an ornithine decarboxylase (ODC) inhibitor, delays the onset of type 1 diabetes (T1D) by reducing β cell stress. However, the mechanism of DFMO action and its human tolerability remain unclear. In this study, we show that mice with β cell ODC deletion are protected against toxin-induced diabetes, suggesting a cell-autonomous role of ODC during β cell stress. In a randomized controlled trial (ClinicalTrials.gov: NCT02384889) involving 41 recent-onset T1D subjects (3:1 drug:placebo) over a 3-month treatment period with a 3-month follow-up, DFMO (125-1,000 mg/m2) is shown to meet its primary outcome of safety and tolerability. DFMO dose-dependently reduces urinary putrescine levels and, at higher doses, preserves C-peptide area under the curve without apparent immunomodulation. Transcriptomics and proteomics of DFMO-treated human islets exposed to cytokine stress reveal alterations in mRNA translation, nascent protein transport, and protein secretion. These findings suggest that DFMO may preserve β cell function in T1D through islet cell-autonomous effects.
Insights
Alpha-difluoromethylornithine (DFMO) shows promise in delaying type 1 diabetes (T1D) by protecting beta cells. This study confirms its safety and suggests DFMO may preserve beta cell function in T1D patients.
Area of Science:
- Endocrinology
- Immunology
- Metabolic Diseases
Background:
- Alpha-difluoromethylornithine (DFMO), an ornithine decarboxylase (ODC) inhibitor, has shown potential in preclinical models to delay type 1 diabetes (T1D) onset.
- The precise mechanism of DFMO's action and its tolerability in humans have remained unclear.
Purpose of the Study:
- To investigate the cell-autonomous role of ODC in beta cell stress.
- To evaluate the safety and efficacy of DFMO in preserving beta cell function in recent-onset T1D patients.
Main Methods:
- Mice with beta cell-specific ODC deletion were assessed for protection against toxin-induced diabetes.
- A randomized controlled trial (NCT02384889) evaluated DFMO safety and tolerability in 41 recent-onset T1D subjects over 3 months.
- Urinary putrescine levels, C-peptide levels, and islet cell gene/protein expression were analyzed.
Main Results:
- Beta cell ODC deletion protected mice from toxin-induced diabetes, indicating a cell-autonomous role.
- DFMO was found to be safe and well-tolerated in T1D patients, meeting the primary outcome.
- DFMO dose-dependently reduced urinary putrescine and preserved C-peptide levels at higher doses, without significant immunomodulation.
- Transcriptomic and proteomic analyses of DFMO-treated human islets revealed modulation of mRNA translation, protein transport, and secretion pathways.
Conclusions:
- DFMO demonstrates safety and tolerability in recent-onset T1D patients.
- The findings suggest DFMO may preserve beta cell function in T1D through cell-autonomous mechanisms involving protein synthesis and secretion pathways.
More Related Videos
Related Concept Videos
Insulin: Biosynthesis, Chemistry, and Preparation
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
Insulin and C-peptide are...
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Dipeptidyl Peptidase 4 Inhibitors
Hormones Regulating Blood Glucose
In addition to accelerating glucose uptake and utilization, insulin has...
Carbohydrate Metabolism
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...

